rizatriptan benzoate

FDA Drug Profile — MAXALT, RIZATRIPTAN BENZOATE, RIZAFILM, rizatriptan benzoate, MAXALT-MLT

rizatriptan benzoate is listed in the FDA National Drug Code directory with 23 NDC codes, marketed under brand names including MAXALT, RIZATRIPTAN BENZOATE, RIZAFILM. Available dosage forms: tablet, tablet, orally disintegrating, film.

Drug details

Generic Name
rizatriptan benzoate
Brand Names
MAXALT, RIZATRIPTAN BENZOATE, RIZAFILM, rizatriptan benzoate, MAXALT-MLT
Application Number
NDA020864
Sponsor
Organon LLC
NDC Codes
23
Dosage Forms
TABLET, TABLET, ORALLY DISINTEGRATING, FILM
Routes
ORAL
Active Ingredients
RIZATRIPTAN BENZOATE

Indications and Usage

1 INDICATIONS AND USAGE Rizatriptan benzoate orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate orally disintegrating tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate orally disintegrating tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate orally disintegrating tablets are administered to treat any subsequent attacks. Rizatriptan benzoate orally disintegrating tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4) ] . Rizatriptan benzoate orally disintegrating tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate orally disintegrating tablets have not been established for cluster headache. Rizatriptan benzoate is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age (1) Limitations of Use : Use only after clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.